Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

Special Operations Forces (SOF) veterans face disproportionate exposure to combat, repeated deployments, and blast-related injuries, and although they are selected for resilience and benefit from strong unit cohesion, they experience elevated rates of posttraumatic stress disorder (PTSD) and related psychological and cognitive problems. Existing psychotherapies and pharmacotherapies address some symptoms but have limited efficacy, poor adherence for some veterans, and do not reliably remediate complex comorbid presentations that include depression, anxiety, cognitive impairment and suicidality. Given this therapeutic gap, there is growing interest in transdiagnostic approaches that can act rapidly and address multiple symptom domains simultaneously. This study examined a clinical psychedelic programme using ibogaine and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) delivered in Mexico to U.S. SOF veterans. Davis and colleagues set out to characterise retrospective changes in PTSD, depression, anxiety, suicidal ideation, cognitive functioning and psychological flexibility reported by veterans before and after a short, intensive course of ibogaine plus inhaled 5-MeO-DMT, and to describe participants' ratings of the personal and spiritual significance of the experience. The authors framed this as an exploratory evaluation intended to identify signals that could justify controlled trials of these lesser‑studied substances for this population.

This was a retrospective, quasi‑experimental one‑group pretest/posttest survey of English‑speaking U.S. SOF veterans who completed a three‑day residential psychedelic programme in Mexico between 2017 and 2019. Participants were recruited by email and asked to provide anonymous retrospective ratings of symptoms for the 30 days before and the 30 days after the treatment. Inclusion criteria included age 18–64, participation in the programme, and English literacy; no monetary compensation was provided. The study protocol, including trigger warnings for sensitive items and options to skip distressing questions, was approved by an independent institutional review board. Programme screening and exclusions were medical and psychological: prospective patients completed physician screening (medication review, medical history, VA disability rating, treatment history, TBI history), clinician psychological intake, laboratory tests (CBC, metabolic panel, urine drug screen) and a 12‑lead ECG; obese patients or those over 55 required a stress test. Exclusions included current eating disorders, psychotic spectrum disorders, bipolar I disorder, or impaired reality testing. Contraindicated medications required tapering under pharmacy supervision. The treatment occurred over three days in a residential setting. Day 1 included group preparatory therapy and administration of a single oral dose of ibogaine hydrochloride (10 mg/kg; 99% purity) with continuous cardiac monitoring, intravenous fluids and medical observation. Day 2 focused on individual and optional group integration supported by programme staff. Day 3 comprised preparatory sessions and sequential inhaled doses of 5-MeO-DMT (initially 5 mg, 15 mg and 30 mg for a nominal total of 50 mg assuming ~15% concentration in toad secretion); participants not achieving observed peak effects could receive additional 30 mg and, if needed, up to 45 mg. Psychological integration occurred after acute effects subsided. Primary outcomes were retrospectively reported PTSD symptoms (PCL‑5), depression (PHQ‑2), anxiety (GAD‑2), suicidal ideation (Depressive Symptom Index Suicidality Subscale), cognitive functioning (MOS‑CF six‑item subscale) and psychological flexibility (AAQ‑II). The survey also collected military history, prior treatment history, demographic information, and ratings of treatment satisfaction and enduring personal/spiritual effects. Analyses used paired t‑tests to compare before/after retrospective scores, Cohen's d to estimate effect sizes, change‑score correlations to relate psychological flexibility to symptom change, and descriptive statistics to summarise satisfaction and enduring effects. Analyses were run in SPSS version 25.

Fifty-one participants provided usable survey data (sample characteristics reported in results). The mean age was 40.4 years (SD 5.6); the sample was primarily male (96%), Caucasian/White (94%), and non‑Hispanic (92%). Educational attainment was high (76% with a bachelor’s degree or higher) and 55% reported being married and cohabiting. Most (96%) had served in Operation Enduring Freedom or Operation Iraqi Freedom; service branches included Navy (75%), Army (18%) and Marine Corps (6%). Deployment counts were substantial (59% reported five or more deployments). Self‑reported head injuries during deployment were common (82%); 57% reported between one and ten head injuries, and 18% reported between one and 20 blast exposures. Prior treatments before the psychedelic programme included nutritional/dietary changes (59%), yoga (55%), psychotherapy (43%), cannabis (43%), and psychiatric medications (41%). On primary outcomes, participants reported large, statistically significant retrospective improvements from one month before to one month after treatment. Paired comparisons indicated reductions in PTSD symptoms (p < .001; Cohen's d = −3.6), depressive symptoms (p < .001; d = −3.7), anxiety symptoms (p < .001; d = −3.1), suicidal ideation (p < .001; d = −1.9) and self‑reported cognitive impairment (p < .001; d = −2.8). Psychological flexibility increased substantially post‑treatment (p < .001; d = 2.9). Changes in psychological flexibility were strongly associated with reductions in cognitive impairment and symptom measures, with correlation magnitudes in the range 0.61–0.75 (p < .001), indicating larger gains in flexibility co‑occurred with larger symptom reductions. The authors note that, by retrospective report, many participants' scores were no longer elevated above standard clinical cutoffs after treatment. Participant evaluations of the programme were highly positive. Overall satisfaction was very high: 80% reported being very or completely satisfied (28% very satisfied; 53% completely satisfied), 92% said they were very likely to recommend the programme, and 96% judged it "much better" than prior treatments. Enduring personal and spiritual effects were commonly reported: 84% rated the experience as one of the top five most personally meaningful of their lives, 88% as spiritually significant, 86% as psychologically insightful and 69% as psychologically challenging. Self‑reported positive changes included increased life satisfaction (77%), sense of life purpose (75%), meaning in life (73%), social relationships (73%), attitudes about life (74%), attitudes about self (72%), mood (59%), behaviours (63%), spirituality (65%), and changed views about the nature of reality (69%).

Davis and colleagues interpret the retrospective findings as preliminary evidence that a short course of ibogaine followed by inhaled 5‑MeO‑DMT may be associated with rapid and large self‑reported reductions in PTSD, depression, anxiety, suicidal ideation and perceived cognitive impairment among SOF veterans. The authors emphasise the speed and magnitude of reported improvements given the limited number of psychedelic exposures, and they highlight the increase in psychological flexibility as a potential mediating mechanism, noting consistency with other studies that link increases in flexibility to improvements in mood and anxiety following psychedelics. The discussion situates these observations within broader literature on psychedelic‑assisted therapies and cognitive flexibility, proposing that rapid gains in psychological flexibility may help explain therapeutic change and could offer advantages over slower‑acting conventional psychotherapies. The authors also note the potential for pairing psychedelic therapies with trauma‑focused psychotherapy to improve adherence and outcomes for veterans who often show high nonresponse and dropout rates with existing treatments. Several important limitations are acknowledged. The design was a retrospective, uncontrolled one‑group pretest/posttest using "then‑test" items, which is vulnerable to recall bias and the "present state effect" whereby current improvements influence recollection of baseline symptoms. The study lacked clinician‑administered diagnostic assessments and objective cognitive testing, precluding confirmation of diagnoses or objective measurement of cognitive change. Expectancy and placebo effects could not be evaluated, and selection bias and the absence of randomisation or blinding limit causal inference. Generalisability is constrained by the predominantly white, male sample of US SOF veterans seeking out‑of‑country treatment. The authors additionally note that, although safety concerns for ibogaine and 5‑MeO‑DMT are known from other sources, their study did not systematically assess adverse events or side effects, which must be examined in future research. Given these caveats, the investigators conclude that their data provide a signal warranting more rigorous evaluation. They call for randomised, double‑blind, placebo‑controlled trials to determine safety and efficacy, for investigation of adverse effects, and for studies disentangling the individual contributions of ibogaine and 5‑MeO‑DMT as well as their potential integration with established trauma‑focused therapies.

This study is presented as the first report of ibogaine combined with 5‑MeO‑DMT administered in a short residential programme for SOF veterans with psychological and cognitive complaints. The authors conclude that their preliminary, retrospective results suggest the combination may offer a rapid, robust and well‑tolerated treatment signal for a range of psychiatric and cognitive symptoms in this population, but they stress that controlled, rigorous research—including randomised, double‑blind, placebo‑controlled trials and systematic safety assessment—is needed before efficacy or clinical utility can be established.